ASCO 2024: HLB's Rivoceranib Plus Camrelizumab Attracts a Liver Cancer Experts

· Liver cancer experts are impressed by the rivoceranib plus camrelizumab combination's efficacy, minimal side effects, and potential to improve patient quality of life.

(From left) Jung Se-ho, CEO of Elevar Therapeutics and Prof. Dr. med. Arndt Vogel MD/PhD, meeting at Eleva's booth at ASCO. (Credit: HLB)

SEOUL, South Korea, June 4, 2024 (IT Times) - HLB, a leading biopharmaceutical company, is making waves at the American Society of Clinical Oncology (ASCO) annual meeting. For the third year in a row, HLB's US subsidiary, Elevar Therapeutics, has secured a large booth to showcase its new liver cancer drug, expected to be approved by the FDA this year.

In particular, Elevar presented additional data from its Phase 3 clinical trial, demonstrating that the rivoceranib plus camrelizumab combination therapy significantly extended overall survival (mOS) to 23.8 months in treated patients. This data is particularly compelling as it represents the longest survival rate observed in liver cancer treatment to date. The positive results have garnered significant interest from specialists worldwide.

Eleva's booth was a hub of activity throughout ASCO, attracting a steady stream of US liver cancer specialists and pharmaceutical executives eager to learn more about the promising new treatment. Key opinion leaders, including Dr. Richard Finn from UCLA School of Medicine, have expressed optimism about the drug's potential, highlighting its strong clinical results and suitability for broad patient populations.

Beyond the efficacy of the drug, other experts focused on the quality of life benefits for patients. Professors like Arndt Vogel and Richard Kim praised the rivoceranib combination for its convenient oral administration and minimal side effects, allowing patients to maintain a higher quality of life during treatment.

HLB plans to meet with the FDA in July to resolve any outstanding issues and expedite the approval process for its drug as a first-ine treatment for liver cancer. The company is confident that once approved, it will be able to quickly gain market share and make up for any time lost due to the delay. Additionally, HLB has plans to pursue further indications for the drug, including second-line treatment for recurrent liver cancer patients.

"The enthusiastic response from US liver cancer specialists at ASCO is extremely encouraging," said Paul Friel, Head of Marketing at Elevar Therapeutics. "We are confident that the rivoceranib plus camrelizumab combination therapy has the potential to become a leading treatment option in the fight against liver cancer."

Source - IT Times : https://www.ittimes.com/news/articleView.html?idxno=35497

ASCO 2024: HLB's Rivoceranib Plus Camrelizumab Attracts a Liver Cancer Experts - IT타임스